24 March 2023
EMA/120619/2023

Key performance indicators (KPIs) to monitor the European clinical trials environment

Metrics on the Clinical Trials Regulation and Clinical Trials Directive

1 – 28 February 2023, edition 11

On the 31 January 2022 the Clinical Trials Regulation (EU) No 536/2014, hereinafter 'CTR', repealing the Clinical Trials Directive 2001/20/EC, hereinafter 'CTD', became applicable and the Clinical Trial Information System (CTIS) was launched. In line with the provisions outlined in Article 97 of the Clinical Trials Regulation, the European Commission shall assess the impact of the Regulation on scientific and technological progress.

This report provides an overview of Key Performance Indicators (KPIs) related to the implementation of the CTR. The Clinical Trials Regulation Metrics report is published on a monthly basis starting in May 2022. The latest and previous reports can be found at this link.

This report is published as part of the business change programme Accelerating Clinical Trials EU (ACT EU), involving the European Commission, the Heads of Medicines Agencies (HMA), Clinical Trial Coordination Group (CTCG) and the Agency.

One of the priority actions of ACT EU focusses on monitoring the implementation of the CTR.

The metrics presented in the report reflect the status of applications in CTIS and EudraCT[1] as of 31 January 2023 for Clinical Trial applications (CTA) submitted between 1-28 February 2023[2] as well as cumulative figures.

[1] EudraCT is the (European Union Drug Regulating Authorities Clinical Trials Database) European database for all interventional clinical trials on medicinal products authorised in the European Union (EEA) under the Clinical Trial Directive and outside the EU/EEA if they are part of a Paediatric Investigation Plan (PIP)
[2] The two 'smoke test' trials, submitted to CTIS for testing purposes just before the CTIS launch, are not counted.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

Clinical Trial Information System (CTIS) and EudraCT metrics

This report shows the key performance indicators (KPIs) generated from EudraCT and CTIS containing information on clinical trials in the EU/EEA.

1.1. Clinical trial applications submitted under the Clinical Trials Regulation in CTIS

Following the mandatory use of CTIS since 31 January 2023, the submission of initial clinical trials has increased significantly in February 2023 by 59% compared to January 2023.

Overall, 976 clinical trial applications (CTAs) have been submitted in CTIS since the launch of the system on 31 January 2022, of which 752 are initial clinical trial applications, 195 are substantial modification applications and 29 are applications for the addition of a new Member State Concerned.

Of the submitted applications during January 2023, 6 are re-submissions of applications that previously, lapsed (2), were withdrawn (3) and were not-authorised (1).

Specifically, the applications submitted in February 2023 include initial clinical trial applications[3], substantial modifications[4] and addition of a new Member State Concerned[5] applications in the selected period.[6]



[3] Initial clinical trials applications are those submitted in accordance with the requirements of Article 5 and Article 11, as applicable, of the Clinical Trials Regulation (EU) No 536/2014

[4] Substantial modifications are those submitted in accordance with the requirements of chapter III of the Clinical Trials Regulation (EU) No 536/2014

[5] Applications to add a new Member States Concerned are submitted in accordance with the requirements of Article 14 of Regulation (EU) No 536/2014

[6] Corrigendum: the graph shows the corrected figures for initial clinical trial applications submitted in July which are 60 and not 58 as displayed in the report edition 4. The incorrect calculation was due to an error in the reporting system.

1.2. CTAs under Clinical Trial Directive (CTD) uploaded by Member States (MSs) in EudraCT, counted as individual clinical trial protocol

The graph below shows the number of CTAs uploaded by the Member States in EudraCT as individual clinical trial protocol, per month during the selected period[7].

Overall 2,336 CTAs have been uploaded in EudraCT, including those ones submitted to the Member States prior to the mandatory use of CTIS for new initial applications applicable since 31st January 2023 and uploaded in EudraCT in February.



1.3. Ongoing clinical trials (CTs)

CTs under the CTR with at least one positive decision in the EU

The term 'ongoing' refers to clinical trials, authorised in at least one Member State Concerned, where the sponsor has notified the start date of the recruitment of patients in CTIS at the clinical investigator sites[8].

As of 31 January 2023, 131 clinical trials were reported as ongoing in CTIS.

CTs under the CTD

In EudraCT there are no fields available to capture recruitment status at the level of the Member States.

1.4. Trial with a decision under the CTR with/without deferral[9] for the protocol

Due to a CTIS known issue, a mitigation measure has been put in place to prevent publication of clinical trials with deferrals. As a consequence, clinical trials with any type of deferrals with a decision issued mid-August onwards are not available in the public domain. This is a temporary measure until the functionality of the deferral mechanism is restored. Sponsors and EU/EEA Members have the

[7] The data for January 2022 in the graph refers to CTA uploaded by the Member State on the 31 January 2022 only.
[8] Details on recruitment status are based on the information reported by the trial sponsor in CTIS
[9] The option to defer the protocol is only available in CTIS.

possibility to apply deferrals to clinical trials data, which will be published in due course once the issue is resolved.

Therefore, information on number of deferrals applied for the protocol will be reinstate once the functionality of the deferral mechanism is restored.

1.5. Mononational-multinational trials with a decision has been issued by the Member States Concerned (MSC) under the Clinical Trials Regulation, broken down per sponsor type (commercial vs. non-commercial) and average number of MSCs[10]

The graph below shows the number of trials for which at least one decision has been issued in CTIS by a Member State Concerned, per month, since 31 January 2022; meaning a trial has been authorised, authorised with conditions, not authorised or trials previously authorised that have now ended. As visible in the graph the number of trials with a decision substantially increased compared to the previous months leading to the cumulative total of clinical trials with a decision rising by 27%, from 251 to a total of 318 clinical trials, of which 8 were reported as ended.



The graph below shows the number of clinical trials for which a decision has been issued by the first MSC, with information whether the trial is a mono- or multinational and in relation to sponsor type.

[10] Details on trial sponsor type, commercial *vs* non-commercial are derived based on information reported at the time of registration of an organisation in OMS: Organisation Management Service database, and are not recorded as such in the clinical trial application form. Commercial classification includes for example industry, pharmaceutical company, while non-commercial classification includes values such as academia, health care facility, micro, small and medium enterprises.



Multinational clinical trials with a decision rose by 40% to a total of 140 with an average of 6 Member States Concerned in CTIS.

1.6. Mononational-multinational trials with a NCA decision and an Ethics Committee opinion have been issued by the Member States under the Clinical Trials Directive, broken down per sponsor type (commercial vs. non-commercial) and average number of MSs

The graph below shows the number of clinical trials, as individual clinical trials protocols, that received a National Competent Authority decision and an Ethics Committee opinion from the first Member State uploading the CTA in EudraCT, per month, since 31 January 2022[11] displayed by upload date in EudraCT. Similarly to graph 1.2 above, graph 1.6 below shows the number of trials for which a decision has been uploaded by the Member States concerned in EudraCT for initial applications that were submitted prior to CTIS mandatory use applicable since 31st January 2023.

The numbers of applications with a NCA decision and Ethics Committee opinion may increase overtime, as soon as additional information is provided in EudraCT by the Member States. The cumulative total rose from 930 to a total of 1,006 clinical trials by end February 2023.

[11] The data for January that appear in the graph below refers to CTA loaded in EudraCT the 31st January having a subsequent decision by the national Competent Authority and Ethic Committee opinion loaded in EudraCT.



The graph below shows the number of clinical trials with a decision and an opinion have been issued, with information whether the trial is a mono- or multinational and in relation to sponsor type.



Considering clinical trials with a decision and an opinion have been issued on average 4 Member States are involved in multinational trials.

1.7. Clinical trials with a decision per phase (i.e. I, II, III, IV, as well as CT first in human or combined phases early (I and II)) under CTR[12]

The graph below shows the number of clinical trials with a decision, broken down per trial phase.

[12] More than one trial phase can be selected for a single trial and it is counted in each trial. The graph shows the applicable trial phases in the selected period.

CTs with a decision in CTIS per phase



1.8. Clinical trials for which a NCA decision and an Ethics Committee opinion have been issued per phase (i.e. I, II, III, IV, as well as CT first in human or combined phases early (I and II)) under CTD

The graph below shows the number of clinical trials, as individual clinical trial protocol, uploaded in EudraCT as of 31 January 2022, with a decision by the National Competent Authority and an opinion by the Ethics Committee have been inserted by the first Member States uploading the CTA in EudraCT, broken down per trial phase.

CTs in EudraCT per phase



1.9. Clinical trials with a decision under CTR, per therapeutic area[13]

The graph below shows the number of clinical trials with a decision in CTIS showing the 15 most frequent therapeutic areas.



[13] In case a clinical trial investigates several therapeutic areas, it is counted in each of such identified therapeutic areas..

1.10. Clinical trials with a NCA decision and an Ethics Committee opinion under CTD, per therapeutic area[14]

The graph below shows the number of clinical trials, as individual clinical trial protocol, for which a decision by the National Competent Authority and an opinion by the Ethics Committee have been inserted by the first Member State uploading the CTA in EudraCT, showing the most frequent 15 therapeutic areas.[15]



1.11. Clinical trials with a decision with an ATMP and per type under CTR

14 clinical trial with a decision included an ATMP, with the following therapeutic types.



[14] In case a clinical trial investigates several therapeutic areas, it is counted in each of such identified therapeutic areas.
[15] The value 'not possible to specify' in the graph above reflects the fact that section E.1.1.2 of the CTA was not filled in

1.12. Clinical trials with a NCA decision and an Ethics Committee opinion, with an ATMP and per type under CTD

There were 35 clinical trials in EudraCT since 31 January 2022, with a decision and an opinion issued by 28 February 2023 by the first Member State uploading the CTA in EudraCT, including an advanced therapy medicinal products.

The graph below shows the number of clinical trials per ATMP type as reported in EudraCT.



1.13. Clinical trial applications under the CTR per applicable trial status during the selected period, broken down per sponsor type: non- commercial/commercial

The graph below shows the number of initial clinical trial applications, per applicable overall trial status[16] and information of sponsor type submitted in CTIS since 31 January 2022.

[16] Overall trial status is the status per application and not per individual Member State Concerned. The Overall trial status it is derived based on defined business rules, for example in an initial trial application is under evaluation in two MSC and authorised in a third MSC, the overall trial status for the application will be : authorised.



1.14. Art 14 applications to add a new Member State Concerned: (re-)submission, authorisation, rejection, lapsed and withdrawn dossiers

As of 31 January 2022 23 clinical trial applications for the addition of a new MSC, foreseen under Article 14 of Regulation (EU) No 536/2014, have been submitted in CTIS for 14 clinical trials. The below graph provides overview status per application submitted until 28 February 2023.[17]



17 The status of a previously lapsed application to add a new Member State Concerned has changed since the last published report to withdrawn.

1.15. CTAs under Article 5 of CTR [full dossier initial applications] per applicable trial status, at EU, at MS level and with Reporting Member State (RMS) details

The graph below shows the number of initial clinical trial applications with full dossier, submitted in accordance with Article 5 of CTR since 31 January 2022, per applicable overall status at EU level.



It can be noted an increase of 14% of clinical trial applications under evaluation, and authorisation of clinical trial applications have increased by 27% compared to the previous reporting period.

The graph below shows the number of initial clinical trial applications with full dossier, submitted in accordance with Article 5 of CTR since 31 January 2022, per applicable status at the level of the Member States Concerned[18].

[18] In multinational clinical trials the same application has been submitted to multiple Member State Concerned, and it is counted in the graph in each applicable MSC.

Member States Concerned



The graph below shows the distribution of appointment of Reporting Member State (RMS)[19], amongst the applicable Member States Concerned, for clinical trial applications on which a decision has been issued for mono- and multinational trials.

[19] RMS is the Reporting Member State appointed in line with the requirements of Article 5 of the Clinical Trials Regulation (EU) No 536/2014



1.16. Number of CTA Article 11 of CTR [partial dossier initial applications with later Part II submission] per applicable trial status during the reporting period, at EU and at MS level

Partial initial applications submitted to CTIS in line with the requirements of Article 11 of the Regulation (EU) No 536/2014 will be considered for future reporting.

1.17. Average time from submission to reporting date[20] (Article 11 and Article 5 of CTR), and to first decision (Article 5 of CTR) for initial applications and Substantial Modifications part I or part I and II

On average it took 90 calendar days to issue a decision, during the selected period, for the 318 initial clinical trial applications. More details can be found in Annex I.

[20] The reporting date is equal to the date of the RMS conclusion on part I assessment

1.18. Number of submitted, validated, authorised, rejected, lapsed and withdrawn Substantial Modification (SM) applications, related to part I / II / I and II, by sponsor type

As of 31 January 2023 141 distinct applications for substantial modifications, foreseen in chapter II of Regulation (EU) No 536/2014, were submitted in CTIS for 94 clinical trials.



1.19. Number of active substances (ASs) in CTR EU trials (mononational and multinational AS) per safety assessing Member States

During the reporting period 14 saMS[21] were appointed for 27 active substances.

The role of safety assessing Member State Concerned (saMS) will be applicable only for active substances investigated in clinical trials in two or more MSC.

[21] Safety Assessing Member State

Number of saMS appointments per Member States



Annex I
Average time from submission to decision for initial CTAs

The table below shows the number of calendar days since the submission of the initial clinical trial application to CTIS up to the time of the first decision of the Member States Concerned.

Please consider that due dates for tasks completion, including decision, in CTIS takes into account rules such as: allowing 2 consecutive working days, the due date cannot fall on weekend nor on a bank holiday in addition to counting the calendar days.

The list of clinical trials below includes resubmitted applications.

#	Submission date	Decision date	Days to Decision
1	09/02/2022	07/04/2022	57
2	15/02/2022	27/04/2022	71
3	15/02/2022	02/06/2022	107
4	20/02/2022	30/05/2022	99
5	24/02/2022	16/06/2022	112
6	28/02/2022	28/03/2022	28
7	03/03/2022	27/06/2022	116
8	04/03/2022	31/05/2022	88
9	04/03/2022	21/06/2022	109
10	07/03/2022	28/06/2022	113
11	10/03/2022	19/05/2022	70
12	15/03/2022	27/04/2022	43
13	16/03/2022	27/06/2022	103
14	24/03/2022	14/06/2022	82
15	24/03/2022	30/06/2022	98
16	28/03/2022	19/07/2022	113
17	28/03/2022	02/11/2022	219
18	29/03/2022	22/06/2022	85
19	31/03/2022	26/07/2022	117
20	01/04/2022	01/06/2022	61
21	05/04/2022	18/07/2022	104
22	06/04/2022	12/07/2022	97
23	08/04/2022	28/06/2022	81
24	14/04/2022	28/07/2022	105
25	14/04/2022	28/07/2022	105
26	18/04/2022	27/05/2022	39
27	19/04/2022	05/07/2022	77
28	19/04/2022	03/08/2022	106
29	21/04/2022	28/07/2022	98
30	22/04/2022	08/07/2022	77
31	22/04/2022	28/07/2022	97
32	22/04/2022	01/08/2022	101
33	22/04/2022	05/08/2022	105

#	Submission date	Decision date	Days to Decision
34	26/04/2022	28/06/2022	63
35	28/04/2022	16/08/2022	110
36	28/04/2022	24/08/2022	118
37	29/04/2022	05/08/2022	98
38	29/04/2022	08/08/2022	101
39	02/05/2022	07/06/2022	36
40	03/05/2022	24/08/2022	113
41	04/05/2022	04/07/2022	61
42	05/05/2022	08/07/2022	64
43	05/05/2022	01/08/2022	88
44	06/05/2022	23/06/2022	48
45	06/05/2022	28/10/2022	175
46	08/05/2022	04/07/2022	57
47	09/05/2022	18/07/2022	70
48	10/05/2022	26/07/2022	77
49	10/05/2022	04/08/2022	86
50	12/05/2022	31/08/2022	111
51	12/05/2022	01/09/2022	112
52	13/05/2022	26/08/2022	105
53	17/05/2022	09/09/2022	115
54	18/05/2022	28/06/2022	41
55	18/05/2022	01/09/2022	106
56	20/05/2022	08/07/2022	49
57	20/05/2022	25/08/2022	97
58	23/05/2022	28/10/2022	158
59	25/05/2022	11/08/2022	78
60	25/05/2022	16/09/2022	114
61	30/05/2022	22/06/2022	23
62	30/05/2022	06/09/2022	99
63	31/05/2022	23/09/2022	115
64	02/06/2022	10/08/2022	69
65	03/06/2022	01/08/2022	59
66	03/06/2022	01/08/2022	59
67	03/06/2022	21/09/2022	110
68	03/06/2022	26/09/2022	115
69	03/06/2022	27/09/2022	116
70	07/06/2022	27/09/2022	112
71	08/06/2022	27/09/2022	111
72	09/06/2022	11/08/2022	63
73	09/06/2022	23/08/2022	75
74	13/06/2022	09/08/2022	57
75	14/06/2022	15/09/2022	93

#	Submission date	Decision date	Days to Decision
76	15/06/2022	12/08/2022	58
77	16/06/2022	09/09/2022	85
78	19/06/2022	03/08/2022	45
79	22/06/2022	08/07/2022	16
80	22/06/2022	12/08/2022	51
81	23/06/2022	15/09/2022	84
82	23/06/2022	26/09/2022	95
83	24/06/2022	12/09/2022	80
84	24/06/2022	12/09/2022	80
85	24/06/2022	03/10/2022	101
86	24/06/2022	20/10/2022	118
87	27/06/2022	12/10/2022	107
88	28/06/2022	10/10/2022	104
89	28/06/2022	14/10/2022	108
90	01/07/2022	07/10/2022	98
91	01/07/2022	13/10/2022	104
92	04/07/2022	12/09/2022	70
93	04/07/2022	13/10/2022	101
94	04/07/2022	23/01/2023	203
95	05/07/2022	26/09/2022	83
96	06/07/2022	01/02/2023	210
97	08/07/2022	26/10/2022	110
98	09/07/2022	26/09/2022	79
99	11/07/2022	23/08/2022	43
100	12/07/2022	28/07/2022	16
101	12/07/2022	24/10/2022	104
102	13/07/2022	18/10/2022	97
103	13/07/2022	10/11/2022	120
104	14/07/2022	20/10/2022	98
105	15/07/2022	12/09/2022	59
106	15/07/2022	14/10/2022	91
107	15/07/2022	19/10/2022	96
108	15/07/2022	24/10/2022	101
109	15/07/2022	08/11/2022	116
110	17/07/2022	08/11/2022	114
111	18/07/2022	29/09/2022	73
112	18/07/2022	10/10/2022	84
113	18/07/2022	11/10/2022	85
114	18/07/2022	24/10/2022	98
115	19/07/2022	03/10/2022	76
116	20/07/2022	22/09/2022	64
117	20/07/2022	03/10/2022	75

#	Submission date	Decision date	Days to Decision
118	20/07/2022	27/10/2022	99
119	21/07/2022	26/07/2022	5
120	21/07/2022	07/10/2022	78
121	21/07/2022	03/11/2022	105
122	21/07/2022	09/11/2022	111
123	25/07/2022	12/10/2022	79
124	25/07/2022	14/11/2022	112
125	26/07/2022	24/10/2022	90
126	27/07/2022	09/11/2022	105
127	28/07/2022	19/09/2022	53
128	28/07/2022	03/10/2022	67
129	29/07/2022	10/11/2022	104
130	01/08/2022	21/11/2022	112
131	02/08/2022	12/10/2022	71
132	02/08/2022	23/11/2022	113
133	03/08/2022	14/10/2022	72
134	03/08/2022	31/10/2022	89
135	03/08/2022	14/11/2022	103
136	04/08/2022	12/10/2022	69
137	04/08/2022	02/11/2022	90
138	05/08/2022	16/09/2022	42
139	05/08/2022	25/10/2022	81
140	09/08/2022	29/11/2022	112
141	10/08/2022	27/10/2022	78
142	10/08/2022	09/11/2022	91
143	11/08/2022	28/11/2022	109
144	11/08/2022	06/12/2022	117
145	11/08/2022	06/12/2022	117
146	12/08/2022	21/11/2022	101
147	12/08/2022	25/11/2022	105
148	12/08/2022	29/11/2022	109
149	12/08/2022	05/12/2022	115
150	12/08/2022	06/12/2022	116
151	12/08/2022	06/12/2022	116
152	15/08/2022	20/10/2022	66
153	16/08/2022	29/11/2022	105
154	16/08/2022	06/12/2022	112
155	17/08/2022	06/12/2022	111
156	18/08/2022	15/11/2022	89
157	19/08/2022	08/11/2022	81
158	19/08/2022	17/11/2022	90
159	19/08/2022	06/12/2022	109

#	Submission date	Decision date	Days to Decision
160	19/08/2022	13/12/2022	116
161	22/08/2022	27/10/2022	66
162	22/08/2022	22/11/2022	92
163	22/08/2022	24/11/2022	94
164	23/08/2022	06/12/2022	105
165	25/08/2022	15/11/2022	82
166	25/08/2022	09/12/2022	106
167	25/08/2022	15/12/2022	112
168	25/08/2022	20/12/2022	117
169	26/08/2022	25/10/2022	60
170	26/08/2022	10/11/2022	76
171	26/08/2022	11/11/2022	77
172	26/08/2022	18/11/2022	84
173	29/08/2022	07/11/2022	70
174	29/08/2022	01/12/2022	94
175	31/08/2022	28/11/2022	89
176	31/08/2022	19/12/2022	110
177	31/08/2022	19/12/2022	110
178	31/08/2022	20/12/2022	111
179	01/09/2022	11/11/2022	71
180	02/09/2022	12/01/2023	132
181	09/09/2022	22/12/2022	104
182	09/09/2022	18/01/2023	131
183	10/09/2022	28/11/2022	79
184	12/09/2022	02/12/2022	81
185	12/09/2022	12/01/2023	122
186	13/09/2022	19/12/2022	97
187	14/09/2022	05/12/2022	82
188	15/09/2022	14/11/2022	60
189	15/09/2022	10/01/2023	117
190	15/09/2022	16/01/2023	123
191	16/09/2022	14/12/2022	89
192	17/09/2022	06/12/2022	80
193	19/09/2022	24/11/2022	66
194	19/09/2022	29/11/2022	71
195	19/09/2022	11/01/2023	114
196	19/09/2022	23/01/2023	126
197	19/09/2022	27/01/2023	130
198	20/09/2022	09/01/2023	111
199	20/09/2022	19/01/2023	121
200	21/09/2022	04/11/2022	44
201	21/09/2022	14/11/2022	54

#	Submission date	Decision date	Days to Decision
202	21/09/2022	16/11/2022	56
203	21/09/2022	24/01/2023	125
204	21/09/2022	24/01/2023	125
205	22/09/2022	27/12/2022	96
206	22/09/2022	01/02/2023	132
207	23/09/2022	06/10/2022	13
208	23/09/2022	31/01/2023	130
209	23/09/2022	03/02/2023	133
210	26/09/2022	06/12/2022	71
211	27/09/2022	22/12/2022	86
212	27/09/2022	17/01/2023	112
213	29/09/2022	22/11/2022	54
214	30/09/2022	14/12/2022	75
215	30/09/2022	18/01/2023	110
216	30/09/2022	23/01/2023	115
217	30/09/2022	02/02/2023	125
218	03/10/2022	03/11/2022	31
219	03/10/2022	14/11/2022	42
220	03/10/2022	07/02/2023	127
221	04/10/2022	06/02/2023	125
222	05/10/2022	22/12/2022	78
223	06/10/2022	03/02/2023	120
224	07/10/2022	13/02/2023	129
225	07/10/2022	13/02/2023	129
226	07/10/2022	13/02/2023	129
227	07/10/2022	13/02/2023	129
228	10/10/2022	15/11/2022	36
229	10/10/2022	30/11/2022	51
230	10/10/2022	15/02/2023	128
231	11/10/2022	26/01/2023	107
232	11/10/2022	09/02/2023	121
233	11/10/2022	14/02/2023	126
234	11/10/2022	16/02/2023	128
235	12/10/2022	19/12/2022	68
236	13/10/2022	02/02/2023	112
237	13/10/2022	07/02/2023	117
238	13/10/2022	15/02/2023	125
239	14/10/2022	17/02/2023	126
240	14/10/2022	23/02/2023	132
241	16/10/2022	13/02/2023	120
242	17/10/2022	02/12/2022	46
243	17/10/2022	22/02/2023	128

#	Submission date	Decision date	Days to Decision
244	18/10/2022	10/02/2023	115
245	18/10/2022	21/02/2023	126
246	19/10/2022	10/01/2023	83
247	19/10/2022	18/01/2023	91
248	19/10/2022	23/01/2023	96
249	19/10/2022	26/01/2023	99
250	19/10/2022	13/02/2023	117
251	20/10/2022	21/12/2022	62
252	20/10/2022	18/01/2023	90
253	20/10/2022	20/01/2023	92
254	20/10/2022	30/01/2023	102
255	20/10/2022	20/02/2023	123
256	21/10/2022	01/02/2023	103
257	21/10/2022	10/02/2023	112
258	21/10/2022	23/02/2023	125
259	21/10/2022	24/02/2023	126
260	21/10/2022	27/02/2023	129
261	26/10/2022	05/12/2022	40
262	26/10/2022	27/02/2023	124
263	27/10/2022	20/02/2023	116
264	28/10/2022	14/12/2022	47
265	31/10/2022	15/12/2022	45
266	31/10/2022	23/12/2022	53
267	31/10/2022	31/01/2023	92
268	01/11/2022	18/11/2022	17
269	03/11/2022	20/12/2022	47
270	03/11/2022	09/02/2023	98
271	03/11/2022	23/02/2023	112
272	04/11/2022	20/12/2022	46
273	04/11/2022	27/01/2023	84
274	04/11/2022	17/02/2023	105
275	04/11/2022	20/02/2023	108
276	07/11/2022	18/01/2023	72
277	07/11/2022	27/02/2023	112
278	07/11/2022	28/02/2023	113
279	08/11/2022	18/01/2023	71
280	08/11/2022	06/02/2023	90
281	08/11/2022	06/02/2023	90
282	09/11/2022	18/12/2022	39
283	10/11/2022	20/02/2023	102
284	10/11/2022	23/02/2023	105
285	14/11/2022	02/02/2023	80

#	Submission date	Decision date	Days to Decision
286	15/11/2022	15/12/2022	30
287	15/11/2022	31/01/2023	77
288	15/11/2022	07/02/2023	84
289	15/11/2022	09/02/2023	86
290	16/11/2022	07/02/2023	83
291	17/11/2022	27/01/2023	71
292	17/11/2022	07/02/2023	82
293	17/11/2022	10/02/2023	85
294	17/11/2022	13/02/2023	88
295	17/11/2022	27/02/2023	102
296	22/11/2022	17/02/2023	87
297	23/11/2022	16/12/2022	23
298	23/11/2022	24/01/2023	62
299	24/11/2022	28/02/2023	96
300	28/11/2022	16/02/2023	80
301	28/11/2022	27/02/2023	91
302	29/11/2022	07/02/2023	70
303	29/11/2022	23/02/2023	86
304	01/12/2022	11/01/2023	41
305	07/12/2022	02/02/2023	57
306	08/12/2022	20/12/2022	12
307	09/12/2022	21/02/2023	74
308	15/12/2022	24/01/2023	40
309	19/12/2022	31/01/2023	43
310	20/12/2022	03/02/2023	45
311	20/12/2022	28/02/2023	70
312	22/12/2022	08/02/2023	48
313	22/12/2022	09/02/2023	49
314	23/12/2022	13/02/2023	52
315	23/12/2022	13/02/2023	52
316	10/01/2023	22/02/2023	43
317	25/01/2023	30/01/2023	5
318	13/02/2023	28/02/2023	15